A Study to See How Safe a New Medicine (NNC6022-0004) is in Healthy People and People Living With Obesity

This study is being done to look at the efficacy single and multiple ascending dose study investigating safety, tolerability, pharmacokinetics, food effect and target engagement in healthy adults including a single cohort in adults living with obesity. Participants will either get NNC6022-0004, (the treatment being tested) or Placebo (a treatment that has no active medicine in it) and which treatment participants get is decided by chance.

NCT Number	NCT07693868
Lead Sponsor	Novo Nordisk A/S
Conditions	Obesity, Elevated High-sensitivity C-reactive Protein (hsCRP)
Enrollment	128 participants
Start Date	2026-07-06
Primary Completion	2027-08-01 (estimated)
Study Completion	2027-08-01 (estimated)
Updated on ClinicalTrials.gov	2026-07-09